Merck Scraps Two Late-Stage Keytruda Studies on Disappointing DataZacks Investment Research • 08/30/24
Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)Business Wire • 08/29/24
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/29/24
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?Zacks Investment Research • 08/27/24
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential ThrombocythemiaBusiness Wire • 08/27/24
The Zacks Analyst Blog Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of DistinctionZacks Investment Research • 08/26/24
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-IIIBusiness Wire • 08/26/24
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA NegotiationsInvestors Business Daily • 08/15/24
Merck's Weakness Could Mean Profits With This Bearish Option TradeInvestors Business Daily • 08/14/24